Evidence in favour
- 27 distinct acquisition events survive duplicate and security-type controls.
- Participation spans 20 named insiders rather than one filing source.
- The latest qualifying evidence is fresh, dated 31 Jul 2026.
Company insider dossier
Ionis Pharmaceuticals Inc insider intelligence
IONS filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
66/100
Accumulation bias
93/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 31 Jul 2026
Investment committee read
Accumulation bias
Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.
Watch for market confirmationDecision risks
- Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 56.56 USD
- One-week move
- +9.3%
- Four-week move
- -2.9%
- Fair-value gap
- +10.6%
- Trend signal
- Inactive
- Relative strength
- -30.9
Directional balance
Controlled event mix
45.8%acquisition
- Acquisition events
- 27
- Disposal events
- 32
- Net value
- -$13.3M
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
025 May
501 Jun
1008 Jun
315 Jun
1922 Jun
1829 Jun
806 Jul
613 Jul
020 Jul
227 Jul
003 Aug
010 Aug
Named participants
Insider conviction by person
LOSCALZO, JOSEPHDirector768 events
HAYDEN, MICHAEL RDirector752 events
KORDASIEWICZ, HOLLY B.EVP, Chief Development Officer677 events
MONIA, BRETT PDirector, Chief Executive Officer6610 events
BAROLDI, JOSEPHEVP, Chief Business Officer655 events
BERTHELSEN, SPENCER RDirector634 events
SCHNEIDER, EUGENEEVP, Chf Clinical Develop Ofcr612 events
DIAZ, ALLENE M.Director612 events
KLEIN, JOSEPH IIIDirector5810 events
HANTSON, LUDWIGDirector500 events
REIKES, PETER NDirector500 events
HERMAN, JOAN EDirector500 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable IONS filing ledger
Showing 91 to 112 of 112.
KLEIN, JOSEPH IIIDirector
DisposalCommon equity
8680 sharesCommon Stock
$636.7KDirectional evidence
KLEIN, JOSEPH IIIDirector
AcquisitionCommon equity
10111 sharesCommon Stock
$476.3KDirectional evidence
KLEIN, JOSEPH IIIDirector
DisposalCommon equity
1431 sharesCommon Stock
$106.5KDirectional evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
DisposalCommon equity
1626 sharesCommon Stock
$116.7KDirectional evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
DisposalCommon equity
5619 sharesCommon Stock
$419.0KDirectional evidence
JENNE, KYLEEVP, Chf GL Pdt Str Ofcr
DisposalCommon equity
4902 sharesCommon Stock
$368.5KDirectional evidence
BIRCHLER, BRIANEVP, Corp and Development Ops
DisposalCommon equity
973 sharesCommon Stock
$73.0KDirectional evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
DisposalEquity compensation
10837 sharesRestricted Stock Unit
Not reportedContext evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
AcquisitionCommon equity
10837 sharesCommon Stock
Not reportedContext evidence
BIRCHLER, BRIANEVP, Corp and Development Ops
AcquisitionCommon equity
1875 sharesCommon Stock
Not reportedContext evidence
BIRCHLER, BRIANEVP, Corp and Development Ops
DisposalEquity compensation
1875 sharesRestricted Stock Unit
Not reportedContext evidence
JENNE, KYLEEVP, Chf GL Pdt Str Ofcr
DisposalEquity compensation
12226 sharesRestricted Stock Unit
Not reportedContext evidence
JENNE, KYLEEVP, Chf GL Pdt Str Ofcr
AcquisitionCommon equity
12226 sharesCommon Stock
Not reportedContext evidence
PARSHALL, B LYNNEDirector
DisposalCommon equity
4466 sharesCommon Stock
$340.3KDirectional evidence
PARSHALL, B LYNNEDirector
DisposalCommon equity
534 sharesCommon Stock
$41.1KDirectional evidence
DEVERS, SHANNON L.EVP, Chief Human Resources Ofc
DisposalCommon equity
6193 sharesCommon Stock
$458.6KDirectional evidence
KLEIN, JOSEPH IIIDirector
DisposalOptions and derivatives
10321 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
KLEIN, JOSEPH IIIDirector
DisposalOptions and derivatives
12000 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
KLEIN, JOSEPH IIIDirector
DisposalCommon equity
20105 sharesCommon Stock
$1.5MDirectional evidence
KLEIN, JOSEPH IIIDirector
AcquisitionCommon equity
12000 sharesCommon Stock
$456.7KDirectional evidence
KLEIN, JOSEPH IIIDirector
AcquisitionCommon equity
10321 sharesCommon Stock
$424.0KDirectional evidence
KLEIN, JOSEPH IIIDirector
DisposalCommon equity
2216 sharesCommon Stock
$168.3KDirectional evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.